Longitudinal investigation of TMS as a tool to improve alcohol treatment outcomes

TMS 作为改善酒精治疗结果工具的纵向调查

基本信息

项目摘要

With advances in optogenetic stimulation techniques, preclinical studies have demonstrated that activity in frontal-striatal neural circuits has a causal influence on heavy drinking and alcohol reinstatement. Clinically, however, we have not yet translated this research into a neural circuit based therapeutic technique for patients with alcohol use disorder (AUD). The long term goal of our multidisciplinary research team is to determine the optimal parameters through which non- invasive transcranial magnetic stimulation can be used to improve alcohol drinking outcomes (abstinence, heavy drinking days) among individuals seeking behavioral treatment for AUD. Building on a foundation of several target identification studies and a small double-blinded clinical trial in treatment-engaged AUD patients performed by our group, here we propose a double-blind placebo controlled, randomized study to evaluate the relative efficacy of 2 potential TMS treatment strategies for AUD. Specifically, using the existing infrastructure of the MUSC Intensive Outpatient Treatment Program, consenting participants will be randomized to receive real or sham TMS delivered to the ventral medial prefrontal cortex (vmPFC), or dorsolateral prefrontal cortex (dlPFC) for 20 sessions (2x/day, 10 days) immediately before their daily intensive outpatient therapy sessions. The scientific premise of this 5 year R01 proposal is that, by modulating the neural circuits that regulate alcohol cue-reactivity (Strategy 1, Aim 1, vmPFC) or executive control (Strategy 2, Aim 2, dlPFC) it will be possible to increase alcohol abstinence rates and decrease heavy drinking days over a 4 month period. With our combined scientific expertise in brain stimulation (Hanlon, neuroimaging (Schacht and Hanlon), alcohol use disorder research (Schacht, Anton, Book), and clinical practice with AUD patients (Book, Smith) our research team at MUSC is uniquely suited to develop this critical line of research. The outcomes of the proposed Aims will provide an evidence-based foundation for a multisite clinical trial and will hasten progress towards developing a new neural circuit based treatment for patients with AUD.
随着光遗传学刺激技术的进步,临床前研究已经证明, 额叶-纹状体神经回路的活动对大量饮酒和酒精有因果关系 复职然而,在临床上,我们还没有将这项研究转化为神经回路 酒精使用障碍(AUD)患者的治疗技术。的长期目标 我们的多学科研究团队是为了确定最佳参数, 侵入性经颅磁刺激可用于改善饮酒结果 (禁欲,大量饮酒天)在寻求AUD行为治疗的个体中。 在几项靶点鉴定研究和一项小型双盲临床试验的基础上, 我们的研究小组在接受治疗的AUD患者中进行了一项试验,在此我们提出了一项双盲 安慰剂对照、随机化研究,评价2种潜在TMS的相对疗效 AUD的治疗策略。具体而言,利用MUSC密集型的现有基础设施 门诊治疗计划,知情同意的受试者将随机接受真实的或假手术 TMS传递到腹内侧前额叶皮层(vmPFC)或背外侧前额叶皮层 (dlPFC)进行20次治疗(2次/天,10天),然后立即进行每日强化门诊治疗 心理治疗这个5年R 01提案的科学前提是,通过调节 调节酒精线索反应性(策略1,目标1,vmPFC)或执行控制的神经回路 (战略2,目标2,dlPFC)将有可能提高戒酒率, 4个月内大量饮酒。结合我们在大脑方面的专业知识 刺激(Hanlon),神经影像学(Schacht和Hanlon),酒精使用障碍研究 (Schacht,Anton,Book)和AUD患者的临床实践(Book,Smith)我们的研究团队 在MUSC是唯一适合发展这一研究的关键线。拟议会议的成果 Aims将为多中心临床试验提供循证基础, 为AUD患者开发新的基于神经回路的治疗方法的进展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Colleen A Hanlon其他文献

Colleen A Hanlon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Colleen A Hanlon', 18)}}的其他基金

COCA: Project 4. Neurocircuit Strategy to Decrease Cocaine Cue Reactivity
COCA:项目 4。降低可卡因提示反应性的神经回路策略
  • 批准号:
    10630236
  • 财政年份:
    2019
  • 资助金额:
    $ 68.26万
  • 项目类别:
COCA: Project 4. Neurocircuit Strategy to Decrease Cocaine Cue Reactivity
COCA:项目 4。降低可卡因提示反应性的神经回路策略
  • 批准号:
    10916599
  • 财政年份:
    2019
  • 资助金额:
    $ 68.26万
  • 项目类别:
Longitudinal investigation of TMS as a tool to improve alcohol treatment outcomes
TMS 作为改善酒精治疗结果工具的纵向调查
  • 批准号:
    10245130
  • 财政年份:
    2019
  • 资助金额:
    $ 68.26万
  • 项目类别:
Longitudinal investigation of TMS as a tool to improve alcohol treatment outcomes
TMS 作为改善酒精治疗结果工具的纵向调查
  • 批准号:
    10052962
  • 财政年份:
    2019
  • 资助金额:
    $ 68.26万
  • 项目类别:
COCA: Project 4. Neurocircuit Strategy to Decrease Cocaine Cue Reactivity
COCA:项目 4。降低可卡因提示反应性的神经回路策略
  • 批准号:
    10404587
  • 财政年份:
    2019
  • 资助金额:
    $ 68.26万
  • 项目类别:
Pilot Projects Core
试点项目核心
  • 批准号:
    10526642
  • 财政年份:
    2017
  • 资助金额:
    $ 68.26万
  • 项目类别:
Impact of vMPFC Brain Stimulation on Outcomes in Treatment-Engaged Cocaine Users
vMPFC 大脑刺激对接受治疗的可卡因使用者的结果的影响
  • 批准号:
    9092998
  • 财政年份:
    2016
  • 资助金额:
    $ 68.26万
  • 项目类别:
Longitudinal study of functional connectivity among cocaine users in treatment
可卡因使用者在治疗中功能连接的纵向研究
  • 批准号:
    9067266
  • 财政年份:
    2014
  • 资助金额:
    $ 68.26万
  • 项目类别:
Investigating the Neurobiologic Basis for Loss of Cortical Laterality in Chronic
研究慢性病患者皮质偏侧性丧失的神经生物学基础
  • 批准号:
    8663383
  • 财政年份:
    2014
  • 资助金额:
    $ 68.26万
  • 项目类别:
Longitudinal study of functional connectivity among cocaine users in treatment
可卡因使用者在治疗中功能连接的纵向研究
  • 批准号:
    8858608
  • 财政年份:
    2014
  • 资助金额:
    $ 68.26万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 68.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 68.26万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 68.26万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 68.26万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 68.26万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 68.26万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 68.26万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 68.26万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 68.26万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 68.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了